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1. Introduction 
Dihydrofolate r ductase is the 'target' for the anti- 
folate drugs, which include the antineoplastic agent 
methotrexate and the antibacterial gent rimeth- 
oprim. Methotrexate, a 2,4-diaminopteridine, is a 
close structural analogue of the substrate folate, a 
2-amino-4~xopteridine, but binds about a thousand 
times more tightly [ 1-3 ]. Trimethoprim is a 2,4-dia- 
minopyrimidine, and compounds of this type also 
bind much more tightly than their 4-oxo analogues 
(eg. [41). 
There appear to be two major differences between 
the binding of methotrexate and that of folate: meth- 
otrexate isprotonated atN1 when bound to the 
enzyme [2-10], while folate is apparently not, and 
the pteridine ring of methotrexate binds to the enzyme 
in an orientation which differs by a rotation of about 
180 ° about its long axis from that adopted by folate 
[ 11-14]. The recent determination f the crystal 
structure of the enzyme-trimethoprim complex [15] 
shows that the orientation of the 2,4-diaminopyrimi- 
dine ring in the binding site is very similar to that of 
the analogous part of methotrexate [11,16]. We now 
report ~3C NMR experiments which confirm this sim- 
ilarity in the binding of the two inhibitors in solution, 
and show that trimethoprim is also protonated when 
bound. 
2. Materials and methods 
Dihydrofolate r ductase was isolated and purified 
from Lactobacillus casei MTX/R as in [17]. Trimeth- 
oprim enriched to 90% with 13C at the 2-position of 
the pyrimidine ring was prepared by condensation of
[ xa C] guanidine with ~-anilino-a-(3,4,5-trimethoxy- 
benzyl) acrylonitrite [24,25]. 
13C NMR spectra were obtained at 50.3 MHz using 
a Bruker WM-200 spectrometer. Samples contained 
0.5 mM enzyme and 0.4-1.0 mM [2-13C] trimethoprim 
in 2H20 containing 50 mM phosphate and 500 mM 
KC1, with a total volume of 3 ml. The pH* (a meter 
reading uncorrected for the isotope ffect on the glass 
electrode) was adjusted with small volumes of 1 M 
2HC1 or KO2H. Spectra were acquired at a sample tem- 
perature of 1 I°C using a spectral width of 10 kHz and 
16384 data points (final digital resolution 1.2 Hz/ 
point); the pulse interval was 0.82 s, and the flip angle 
25 °. Up to 60 000 transients were averaged, and 
before Fourier transformation the free induction 
decay was multiplied by an exponential function to 
improve the signal-to-noise ratio, leading to line-broad- 
ening of 2-5 Hz. Chemical shifts are given with 
respect to external dioxan. 
3. Results and discussion 
As shown in fig.l, when [2.13C]trimethoprim is 
added to L. casei dihydrofolate r ductase at a molar 
ratio to the enzyme of 2:1, two separate resonances 
are seen for the 13C-enriched 2~carbon. At a molar 
ratio of 0 9:1, only the resonance at 89.26 ppm is 
observed, thus identifying this as the resonance of the 
bound trimethoprim and indicating that exchange of 
trimethoprim between bound and free states is slow on 
the NMR time-scale at 1 I°C. (This is to be expected, 
since the rate constant for dissociation of trimethoprim 
from the complex is only 6 s -l at 45°C [18].) 
When the pH* of the sample is increased from 
6.53 to 7.46, the chemical shift of the resonance of 
bound trimethoprim is unaffected, while that of free 
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Fig.1.13C Resonances, measured at 50.3 MHz, of [2-13C]tri - 
methoprim (1 mM) in the presence of L. casei dihydrofolate 
reductase (0.5 mM) at two pH* values. The resonances from 
trimethoprim bound to the enzyme and free in solution are 
labelled band f, respectively. 
trimethoprim shifts downfield. The pH*-dependence 
of the chemical shifts of these two signals is shown in 
more detail in fig.2. The resonance of free trimeth- 
oprim shows a marked downfield shift with increasing 
pH* as the molecule deprotonates; the total titration 
shift, measured in the absence of enzyme, is 7.09 ppm, 
from 87.97 ppm to 95.06 ppm with an apparent pK a 
(in 2H20 containing 0.5 M KC1, and based on pH* 
measurements) of 7.7. By contrast, he chemical shift 
of the resonance of bound trimethoprim remains con- 
stant over pH* 5 -8 .  
The chemical shift of the 2-carbon of bound tri- 
methoprim is clearly much closer to that of the pro- 
tonated than to that of the unprotonated molecule. 
The difference of 1.29 ppm between the chemical 
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Fig.2. The pH*-dependence of the chemical shift of the 2 -~ 3C 
resonance oftrin]ethoprim free (o) and bound to L. casei 
dihydrofolate r ductase (A). Data between pH* 5 and 8 were 
obtained from a sample containing dihydrofolate r ductase 
and 2 molar equivalents of [ 2 -~ 3C] trimethoprim. The enzyme 
is unstable above pH* 8, and the data point for free trimeth- 
oprim at pH* 9.5 was obtained in the absence of enzyme. 
The solid line is calculated for pK 7.70 and a chemical shift 
difference between protonated and unprotonated forms of 
7.09 ppm. 
shift of the bound and the protonated molecules can, 
as discussed below, readily be accounted for by the 
kind of environmental effects expected for a bound 
ligand, whereas the difference of 5.80 ppm between 
the shifts of the bound and the unprotonated mole- 
cules is outside the range expected for such effects in 
diamagnetic, non-haem proteins. It is therefore highly 
probable that, like methotrexate, trimethoprim is pro- 
tonated when bound to dihydrofolate reductase. The 
pH*-dependence of the chemical shift of the 2-carbon 
resonance of the bound ligand up to pH* 8 shows that 
there is no detectable deprotonation f the ligand over 
this range, and hence that its pK nmst have increased 
by at least 2 units on binding. 
We have earlier used UV absorption spectroscopy 
in an attempt to determine the charge state of enzyme- 
bound methotrexate and trimethoprim [2]. In these 
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experiments, a pH-dependence of the UV difference 
spectrum was observed which was ascribed to depro- 
tonation of the enzyme-bound ligand, and it was con- 
cluded that the pK of trimethoprim was increased by 
only --49.8 units on binding. The present 13C NMR 
experiments, which provide much more direct infor- 
mation on the charge state of the molecule, show that 
the increase in pK must be much greater than this. 
Similarly, I3C NMR experiments on the binding of 
[2-13C]methotrexate of the L. casei reductase [3] 
showed that the UV experiments also led to an under- 
estimate of  the increase in pK of this ligand on bind- 
ing; both methotrexate and trimethoprim have pK 
values ;>9.5-10 when bound to the reductase. The 
pH-dependence of the UV spectrum must arise from 
the ionisation of some group or groups on the enzyme. 
The substantial increase in pK of trimethoprim on 
binding makes a major contribution to the observed 
change in 2-13C chemical shift on binding. However, 
this is not the sole component of the change in chem- 
ical shift, since, as noted above, the resonance of tri- 
methoprim in the bound state is 1.29 ppm downfield 
of that of free protonated trimethoprim. This second 
component of the chemical shift change obviously 
reflects the environment of  the protonated trimeth- 
oprim in the binding site. From our previous calcula- 
tions [18], any ring-current contributions (from 
Phe-30 or the benzyl ring of  trimethoprim itself) are 
likely to be small. Two other probable contributions 
can be identified. In the crystal, the carboxylate of 
Asp-26 (L. casei numbering) is close to N1 of bound 
methotrexate [11,1 6] or trimethoprim [15]. This 
interaction is doubtless responsible for the increase in 
pK of these ligands on binding, but the proximity of 
the carboxylate group will also lead to an electric field 
shift of  the 2-13C resonance, whose sign wilt depend 
on the relative polarisability of the bonds to this car- 
bon [19-21 ]. In addition, the 2-amino group proba- 
bly forms a hydrogen-bond to Thr 116 (L. casei num- 
bering) [ 11,15,1 6] and this will lead to a shift of the 
resonance of the directly bonded carbon. For example, 
in aniline the C a resonance is 2.1-2.7 ppm further 
downfield in dimethylsulphoxide or acetone solution 
than in carbon tetrachloride solution, presumably due, 
at least in part, to hydrogen-bonding of the amino 
group [22]. 
Whatever the precise origin of this second compo- 
nent of  the change in chemical shift on binding, it is 
notable that it is the same for trimethoprim (1.29 ppm) 
as for methotrexate (1.32 ppm; [3]). This must imply 
that the environment of the 2-carbon, and hence prob- 
ably that of  the amidinium moiety (N1, C2, N3 and 
the 2-amino group) as a whole, is identical in the 
enzyme-trimethoprim and enzyme-methotrexate 
complexes in solution. In view of the considerable sen- 
sitivity of 13C chemical shifts to environment and elec- 
tron distribution (e.g. [23]) this statement can be 
made with some confidence; it is clearly consistent 
with recent crystallographic work [ 15 ]. This close 
similarity in the binding of the corresponding parts of 
trimethoprim and methotrexate justifies one of the 
central assumptions of our analysis of the proton 
chemical shift changes of trimethoprim on binding 
[18], and indeed one of the two possible conforma- 
tions for trimethoprim bound to the enzyme in solu- 
tion proposed from this analysis [18] is very similar 
to that subsequently found crystallographically [15]. 
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